Warning (2) : Undefined array key "profile" [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 242]
Warning (2) : Trying to access array offset on value of type null [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 242]
Warning (2) : Undefined array key "profile" [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 243]
Warning (2) : Trying to access array offset on value of type null [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 243]
Warning (512) : Unable to emit headers. Headers sent in file=/var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php line=36 [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 71]
Warning (2) : Cannot modify header information - headers already sent by (output started at /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 164]
Warning (2) : Cannot modify header information - headers already sent by (output started at /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 197]
Warning (2) : Cannot modify header information - headers already sent by (output started at /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 236]
Guardant Health, Inc. - Market capitalization
Guardant Health, Inc.
GH

$3.79 B
Marketcap
$30.68
Share price
Country
N/A
Change (1 day)
N/A
Year High
N/A
Year Low

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

marketcap